Stock Scorecard



Stock Summary for Viking Therapeutics Inc (VKTX) - $51.53 as of 11/20/2024 8:51:25 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for VKTX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for VKTX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for VKTX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for VKTX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for VKTX (47 out of 90)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0

Latest News for for VKTX

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - Viking Therapeutics ( NASDAQ:VKTX ) 11/20/2024 6:26:00 PM
What the Options Market Tells Us About Viking Therapeutics - Viking Therapeutics ( NASDAQ:VKTX ) 11/18/2024 5:30:00 PM
3 Things You Need to Know if You Buy Viking Therapeutics Today 11/18/2024 9:45:00 AM
Is It Too Late to Buy Viking Therapeutics Stock? 11/17/2024 12:05:00 PM
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. 11/16/2024 10:30:00 AM
Market Whales and Their Recent Bets on VKTX Options - Viking Therapeutics ( NASDAQ:VKTX ) 11/15/2024 5:01:00 PM
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? 11/15/2024 9:05:00 AM
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate 11/14/2024 8:00:00 PM
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? 11/14/2024 12:15:00 PM
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? 11/13/2024 2:45:00 PM

Financial Details for VKTX

Company Overview

Ticker VKTX
Company Name Viking Therapeutics Inc
Country USA
Description Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 2/5/2025

Stock Price History

Last Day Price 51.53
Price 4 Years Ago 5.63
Last Day Price Updated 11/20/2024 8:51:25 PM EST
Last Day Volume 3,496,787
Average Daily Volume 5,399,164
52-Week High 99.41
52-Week Low 11.21
Last Price to 52 Week Low 359.68%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -28.10
Free Cash Flow Ratio 6.17
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 36.47
Total Cash Per Share 8.35
Book Value Per Share Most Recent Quarter 8.18
Price to Book Ratio 6.06
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 111,436,000
Market Capitalization 5,742,297,080
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -24.73%
Reported EPS 12 Trailing Months -0.93
Reported EPS Past Year -0.68
Reported EPS Prior Year -0.92
Net Income Twelve Trailing Months -99,151,000
Net Income Past Year -85,895,000
Net Income Prior Year -68,867,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 930,440,000
Total Cash Past Year 362,079,000
Total Cash Prior Year 155,485,000
Net Cash Position Most Recent Quarter 930,440,000
Net Cash Position Past Year 362,079,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 348,419,000
Total Stockholder Equity Prior Year 145,322,000
Total Stockholder Equity Most Recent Quarter 911,448,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -74,249,000
Free Cash Flow Per Share Twelve Trailing Months -0.67
Free Cash Flow Past Year 0
Free Cash Flow Prior Year 0

Options

Put/Call Ratio 0.31
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.05
MACD Signal 0.66
20-Day Bollinger Lower Band 47.33
20-Day Bollinger Middle Band 62.18
20-Day Bollinger Upper Band 77.02
Beta 0.99
RSI 36.88
50-Day SMA 54.16
150-Day SMA 23.83
200-Day SMA 19.43

System

Modified 11/19/2024 3:39:43 PM EST